ANIX (Anixa Biosciences) PS Ratio: (As of Jun. 30, 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.85
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Anixa Biosciences's share price is $2.85. Anixa Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00. Hence, Anixa Biosciences's PS Ratio for today is .

The historical rank and industry rank for Anixa Biosciences's PS Ratio or its related term are showing as below:

During the past 13 years, Anixa Biosciences's highest PS Ratio was 708.57. The lowest was 13.13. And the median was 225.50.

ANIX's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.37
* Ranked among companies with meaningful PS Ratio only.

Anixa Biosciences's Revenue per Sharefor the three months ended in Apr. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 was $0.00.

During the past 13 years, Anixa Biosciences's highest 3-Year average Revenue per Share Growth Rate was 260.50% per year. The lowest was -59.80% per year. And the median was -5.75% per year.

Back to Basics: PS Ratio


Anixa Biosciences  (NAS:ANIX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Anixa Biosciences PS Ratio Related Terms


Anixa Biosciences PS Ratio Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences PS Ratio Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 265.00 0.00 451.43 0.00 0.00

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANIX vs BMEA, PMN, ATRA: PS Ratio Comparison

For the Biotechnology subindustry, Anixa Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's PS Ratio falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Anixa Biosciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=2.85/0
=

Anixa Biosciences's Share Price of today is $2.85.
Anixa Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Apr. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.85
Price